Mercado mundial de la enfermedad de Hashimoto: tendencias de la industria y pronóstico hasta 2029

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado mundial de la enfermedad de Hashimoto: tendencias de la industria y pronóstico hasta 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Páginas
  • Número de tablas: 220
  • Número de figuras: 60

Global Hashimotos Disease Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2022 –2029
Diagram Tamaño del mercado (año base)
USD 973.69 Billion
Diagram Tamaño del mercado (año de pronóstico)
USD 1,282.16 Billion
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Mercado mundial de la enfermedad de Hashimoto, por tipo (relacionado con el estrés, relacionado con infecciones, relacionado con enfermedades autoinmunes, relacionado con el medio ambiente, relacionado con enfermedades, mixto, otros), tratamiento (terapia de reemplazo hormonal T-3, terapia de reemplazo hormonal T-4, otros), forma farmacéutica (comprimidos, cápsulas, polvos, otros), vía de administración (oral, parenteral, otros), diagnóstico (pruebas de anticuerpos, pruebas de función tiroidea, otros), usuarios finales (hospitales, clínicas especializadas, atención domiciliaria, otros), canal de distribución (farmacia hospitalaria, farmacia minorista, farmacia en línea, otros) – Tendencias de la industria y pronóstico hasta 2029

Hashimoto

Análisis y tamaño del mercado

En los últimos años, se prevé que el mercado de la enfermedad de Hashimoto crezca rápidamente durante el período de pronóstico. La ingesta diaria recomendada (IDR) de yodo, según la Organización Mundial de la Salud (OMS), es de 150 mcg por día, que es suficiente para más del 95 por ciento de todas las personas sanas, y las mujeres embarazadas y lactantes requieren más. La ingesta excesiva de yodo es la principal razón que actúa como desencadenante para las personas que ya corren el riesgo de padecer la enfermedad de Hashimoto. La enfermedad de Hashimoto es una enfermedad de la glándula tiroides que afecta a muchas personas. Puede afectar a cualquier persona a cualquier edad, pero es más común en mujeres de mediana edad. Es causada por el ataque del sistema inmunológico a la glándula tiroides. Puede llevar meses o incluso años diagnosticar la enfermedad y que los niveles de hormona tiroidea caigan por debajo de lo normal. Las personas con antecedentes familiares de disfunción tiroidea tienen más probabilidades de desarrollar la enfermedad de Hashimoto.

Data Bridge Market Research analiza que el mercado de la enfermedad de Hashimoto se valoró en USD 973,69 millones en 2021 y se espera que alcance los USD 1.282,16 millones para 2029, registrando una CAGR del 3,50% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

La enfermedad de Hashimoto es una afección que afecta a la glándula tiroides. La enfermedad de Hashimoto también se conoce como tiroiditis linfocítica crónica, tiroiditis de Hashimoto o tiroiditis autoinmune. La glándula tiroides produce hormonas que regulan y mantienen casi todas las actividades metabólicas del cuerpo (cómo convierte los alimentos en energía). La tiroiditis de Hashimoto es una afección autoinmune en la que el sistema inmunológico identifica erróneamente la tiroides y la afecta.

Alcance del informe y segmentación del mercado

Métrica del informe

Detalles

Período de pronóstico

2022 a 2029

Año base

2021

Años históricos

2020 (Personalizable para 2019 - 2014)

Unidades cuantitativas

Ingresos en millones de USD, volúmenes en unidades, precios en USD

Segmentos cubiertos

Type (Stress Related, Infection Related, Autoimmune Related, Environmental Related, Disease Related, Mixed, Others), Treatment (T-3 Hormone Replacement Therapy, T-4 Hormone Replacement Therapy, Others), Dosage Form (Tablets, Capsule, Powder, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Antibody Tests, Testing Thyroid Function, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Provell Pharmaceuticals, LLC (US), Alvogen (US), Piramal Enterprises Ltd. (US), Dr. Reddy’s Laboratories Ltd. (India), Pfizer Inc. (US), Fresenius Kabi AG (Germany), Bio-Rad Laboratories, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Hashimoto’s Disease Market Dynamics

Drivers

  • Increasing prevalence of hypothyroidism

The rising prevalence of hypothyroidism is estimated to enhance the Hashimoto’s disease market's growth. When the thyroid gland is injured by the immune system, it cannot produce enough thyroid hormones to meet the body's needs, resulting in Hashimoto's hypothyroidism. Thyroid hormones control metabolism, which is the process of converting food into energy.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of Hashimoto’s disease market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get Hashimoto’s disease, further estimated to enhance the market’s growth rate.

  • Surging incidences of autoimmune disease

The increasing incidences of autoimmune disease is anticipated to influence the growth of Hashimoto’s disease market. Rheumatoid arthritis, lupus and type 1 diabetes are among the various autoimmune disease that increases the risk of Hashimoto’s disease and further flourish the markets growth during the forecast period of 2022-2029.

Furthermore, rising initiatives by public and private organizations to spread awareness and family history with thyroid diseases will expand the Hashimoto’s disease market. Additionally, rising radiation exposure and high consumption alcohol and alcohol will result in the expansion of Hashimoto’s disease market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Hashimoto’s disease market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the Hashimoto’s disease market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Hashimoto’s disease market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Hashimoto’s disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Hashimoto’s disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

In the United States, Hashimoto's disease is the most frequent cause of hypothyroidism, affecting around 5% of the population. It affects mostly adult females and usually appears between the ages of 40 and 60. Females are at least 8 times more likely than males to be affected.

Hashimoto’s disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hashimoto’s Disease Market

Over the projected period, the Hashimoto’s disease market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The Hashimoto’s disease market has also been hampered by the supply chain slowness.

Global Hashimoto’s Disease Market Scope

The Hashimoto’s disease market is segmented on the basis of type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Stress Related
  • Infection Related
  • Autoimmune Related
  • Environmental Related
  • Disease Related
  • Mixed
  • Others

Treatment

  • T-3 Hormone Replacement Therapy
  • T-4 Hormone Replacement Therapy
  • Others

Diagnosis

  • Antibody Tests
  • Testing Thyroid Function
  • Thyroxine (T-4) Test
  • Thyroid Stimulating Hormone (TSH) Test
  • Others

Dosage form

  • Tablets
  • Capsule
  • Powder
  • Others

Route of Administration

  • Oral
  • Topical
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Hashimoto’s Disease Market Regional Analysis/Insights

The Hashimoto’s disease market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Hashimoto’s disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Hashimoto’s disease market because of the growing number of research and development in autoimmune disorders and rising healthcare expenditure in this region. Additionally, the presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to rising population and surging number of generic manufacturers in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Hashimoto’s Disease Market Share Analysis

The Hashimoto’s disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Hashimoto’s disease market.

Some of the major players operating in the Hashimoto’s disease market are:

  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Eli Lilly and Company (US)
  • Merck & Co., Inc. (US)
  • AstraZeneca (UK)
  • Johnson & Johnson Private Limited (US)
  • Cipla Inc. (US)
  • Abbott (US)
  • AbbVie Inc. (US)
  • Merck KGaA (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupino (India)
  • Provell Pharmaceuticals, LLC (Estados Unidos)
  • Alvogen (Estados Unidos)
  • Piramal Enterprises Ltd. (Estados Unidos)
  • Laboratorios Dr. Reddy Ltd. (India)
  • Pfizer Inc. (Estados Unidos)
  • Fresenius Kabi AG (Alemania)
  • Laboratorios Bio-Rad, Inc. (Estados Unidos)
  • Takeda Pharmaceutical Company Limited (Japón)
  • Sanofi (Francia)
  • F. Hoffmann-La Roche Ltd. (Suiza)


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Hashimoto’s Disease Market will be worth USD 1,282.16 million by 2029 during the forecast period.
The Hashimoto’s Disease Market growth rate is 3.50% during the forecast period.
Increasing prevalence of hypothyroidism, Increasing investment for healthcare infrastructure, Growing number of geriatric population and Surging incidences of autoimmune disease are the growth drivers of the Hashimoto’s Disease Market.
The type, treatment, diagnosis, dosage form, route of administration, end-users and distribution channel are the factors on which the Hashimoto’s Disease Market research is based.
Major companies in the Hashimoto’s Disease Market are GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Provell Pharmaceuticals, LLC (US), Alvogen (US), Piramal Enterprises Ltd. (US), Dr. Reddy’s Laboratories Ltd. (India), Pfizer Inc. (US), Fresenius Kabi AG (Germany), Bio-Rad Laboratories, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland).